IP Library Granted Patent US 6,956,105
Granted Patent B2
US 6,956,105 · App. 10/308,373 · Granted Oct 18, 2005

Chandra: a Th1-specific protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,956,105
App. No.
10/308,373
Granted
Oct 18, 2005
Kind
B2
Abstract

The present invention provides nucleic acid and protein sequences for a novel Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of Th1 lymphocytes, for the identification of molecules that associate with and/or modulate the activity of Chandra, to diagnose any of a number of conditions associated with Th1 or Th2 cell activity, or to modulate the number and/or activity of Th1 or Th2 lymphocytes in a mammal.

Claims (10)

1. An isolated polypeptide having at least about 95% amino acid sequence identity to SEQ ID NO:1 over the full-length of SEQ ID NO:1, and said polypeptide possessing the ability to inhibit IL-4 dependent signalling.

2. The polypeptide of claim 1 , wherein said polypeptide specifically binds to polyclonal antibodies generated against a polypeptide comprising an amino acid sequence of SEQ ID NO:1.

3. The polypeptide of claim 1 , wherein said polypeptide comprises an amino acid sequence of SEQ ID NO:1.

4. The polypeptide of claim 1 , wherein said polypeptide is expressed in Th1 lymphocytes.

5. The polypeptide of claim 1 , wherein said polypeptide inhibits IL-4 activity in Th2 cells.

6. The polypeptide of claim 1 , wherein said polypeptide inhibits Th2 cell differentiation and production.

7. The polypeptide of claim 1 , wherein said polypeptide is a polymorphic variant of SEQ ID NO:1, wherein an isoleucine residue is substituted for a valine residue at amino acid position 11.

8. The polypeptide of claim 1 , wherein said polypeptide is a polymorphic variant of SEQ ID NO:1, wherein an alanine residue is substituted for a glycine residue at amino acid position 3.

9. An isolated polypeptide having the amino acid sequence of SEQ ID NO:1.

10. The polypeptide of claim 1 , wherein said polypeptide promotes Th1 cell differentiation and production.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2005
From: AMGEN SF, LLC
To: AMGEN INC.
Reel/Frame 016871/0736 →
MERGER Recorded Jun 7, 2005
From: TULARIK INC.
To: ARROW ACQUISITION, LLC
Reel/Frame 016309/0003 →
CHANGE OF NAME Recorded Jun 7, 2005
From: ARROW ACQUISITION, LLC
To: AMGEN SF, LLC
Reel/Frame 016309/0812 →